Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL6187599

CCCc1ccc(F)cc1.N

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 3/20 0.54
LMNA P02545 2/20 0.51
ALDH1A1 P00352 1/20 0.51
GAA P10253 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
AOC3 Q16853 1/20 0.50
HPGD P15428 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
LPL P06858 1/20 0.48
LIPG Q9Y5X9 1/20 0.48
PTGS1 P23219 1/20 0.47
PTGS2 P35354 1/20 0.47
PLK1 P53350 1/20 0.47
MAOB P27338 1/20 0.46
KMT2A Q03164 1/20 0.46
IDO1 P14902 1/20 0.46
LOXL2 Q9Y4K0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17068942 0.97 TAAR1 (0.56) TAAR1LMNAALDH1A1GAATDP1
SCHEMBL371244 0.97 TAAR1 (0.56) TAAR1LMNAALDH1A1GAATDP1
Hydrochloric Acid SCHEMBL7988601 0.95 TAAR1 (0.54) TAAR1LMNAALDH1A1GAATDP1
Dimethylamine SCHEMBL4661334 0.90 TAAR1 (0.61) TAAR1LMNAALDH1A1GAATDP1
SCHEMBL7552100 0.90 MAOB (0.59) TAAR1LMNAALDH1A1GAATDP1
SCHEMBL8511928 0.90 TAAR1 (0.56) TAAR1LMNAALDH1A1GAATDP1
SCHEMBL8990619 0.88 MAOB (0.57) TAAR1LMNAALDH1A1GAATDP1
SCHEMBL8990730 0.88 MAOB (0.57) TAAR1LMNAALDH1A1GAATDP1
Bicarbonate SCHEMBL3434734 0.86 TDP1 (0.58) TAAR1LMNAALDH1A1GAATDP1
SCHEMBL12013124 0.84 LTA4H (0.51) TAAR1LMNAALDH1A1GAATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130310384-A1 Sulfonamide-Containing Compounds THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2013-11-21 US disclosed
EP-1286975-B1 BICLYCLIC CYCLOHEXYLAMINES AND THEIR USE AS NMDA RECEPTOR ANTAGONISTS WARNER LAMBERT CO (US) 2005-08-24 EP disclosed
US-6794402-B2 Bicyclic cyclohexylamines and their use as NMDA receptor antagonists WARNER-LAMBERT COMPANY 2004-09-21 US disclosed
US-20030236252-A1 Bicyclic cyclohexylamines and their use as nmda receptor antagonists NIKAM SHAM SHRIDHAR (US) 2003-12-25 US disclosed
CN-1438996-A Bicyclic cyclohexylamines and their use NMDA receptor antogonists WARNER LAMBERT CO (US) 2003-08-27 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130310384-A1 Sulfonamide-Containing Compounds BACE1, BACE2, GSAP TAAR1 4343/4885LMNA 2049/4885ALDH1A1 3025/4885
US-20030236252-A1 Bicyclic cyclohexylamines and their use as nmda receptor antagonists GRIN1, GRIN2C, GRIN2A TAAR1 349/4885LMNA 2062/4885ALDH1A1 2372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.